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Sphingosine 1-phosphate (S1P) is a sphingolipid mediator that is
involved in diverse biological functions. Local administration of S1P
causes inflammation coupled to a large eosinophil (EO) recruitment
in the rat-paw tissue. The inflammatory response is accompanied
by an increase in S1P receptors, namely S1P1, S1P2, S1P3, and by an
enhanced expression of CCR3, which is the main chemokine recep-
tor known to be involved in EO function. Human EOs constitutively
express S1P1 and, at a lower extent, S1P2, S1P3 receptors. S1P in
vitro causes cultured human EO migration and an increase in S1P
receptor mRNA copies and strongly up-regulates CCR3 and RANTES
(regulated on activation, normal T cell-expressed and secreted)
message levels; in particular CCR3 is up-regulated 18,000-fold by
S1P. A blocking anti-CCR3 Ab inhibits S1P-induced chemotaxis,
implying that S1P acts as specific recruiting signal for EOs not only
through its own receptors but also through CCR3. These results
show that S1P is involved in EO chemotaxis and contribute to shed
light on the complex mechanisms underlying EO recruitment in
several diseases such as asthma and some malignancies.
CCR3  RANTES  eosinophil migration  inflammation
Sphingolipids are ubiquitously expressed in all eukaryotic cellmembranes and much attention has been focused in this past
decade on the role of the sphingolipid metabolites, ceramide,
sphingosine, and in particular on its phosphorylated product
sphingosine-1-phosphate (S1P). S1P is a lipid mediator that has
been shown to act inside cells to regulate survival. The cloning
and the characterization of different receptor isoforms, together
with the finding that S1P is secreted by the platelets (1), has
strengthened the notion that S1P acts also as an extracellular
signaling molecule. It is now well established that S1P is the
natural ligand for a family of G protein-coupled receptors
originally known as the endothelial differentiation genes and
recently renamed, S1P receptors (2) (S1PRs). To date, it is
known that there are five specific receptors for S1P, that are
S1P1, S1P2, S1P3, S1P4, and S1P5 (2). These receptors can couple
to different G-proteins to elicit a wide array of cellular responses
(3, 4) and modulate calcium release. S1P can activate monocytes
(5, 6) endothelial cells (7, 8), mast cells (9, 10), and asthmatic
smooth muscle cells (11) as well as mediate lymphocyte infil-
tration (12).
Sphingosine is converted to S1P by the enzyme sphingosine
kinase (SphK). SphK is expressed both in humans and animals
and two mammalian isozymes have been characterized as SphK1
and Sphk2. This enzyme is mainly located in the cytosol and, by
using adenosine triphosphate as phosphate donor, catalyzes the
phosphorylation of D-erythrosphingosine to S1P. Many external
stimuli activate the enzyme SphK to generate S1P in particular
cytokines such as tumor necrosis factor  (TNF-) (13) and
IL-1 (14) and cross-linking of the Ig receptor FcRI (15). Thus,
it has been proposed that S1P is not only involved in disorders
such as cancer (16, 17) and atherosclerosis (18), but it is also in
inflammation (6, 19). There are many studies that have indirectly
suggested a role of S1P in inflammation, but at the present stage,
studies mainly address the role of this mediator in vitro by using
cells or isolated tissues. Here, we have determined whether
exogenous S1P, in a pathophysiologically relevant concentration,
can cause inflammation in vivo in rats. Administration of exog-
enous S1P causes an edema that is fast in onset and accompanied
by a large eosinophil (EO) infiltrate. Similarly, i.p. administra-
tion of S1P rapidly recruits EOs into the peritoneal cavity. The
edema formation is accompanied by a selective increase in the
rat-paw tissue of CCR3. In vitro experiments performed by using
highly purified human EOs demonstrated that EOs constitu-
tively express higher mRNA levels of S1P1 and, to a lower extent,
S1P2 and S1P3. Challenging of EOs in vitro with S1P causes
chemotaxis coupled with a strong up-regulation of CCR3 and
RANTES (regulated on activation, normal T cell-expressed and
secreted) message. These data imply that, in inflammatory
events in which S1P is released, EOs could be involved in an
immune response that is most likely of the Th2 type.
Materials and Methods
EO Purification and Flow Cytometry Analysis. Blood samples were
obtained from subjects who underwent clinical examination at
the Allergy and Clinical Immunology Section at the Seconda
Universita` di Napoli. All of the patients were informed fully of
the study and gave written consensus to the procedure. EOs were
isolated from the blood of patients as described (20), with minor
modifications, by using immunomagnetic beads and the mag-
netic cell separation system (MACS). Diluted whole blood (1:5
dilution) was layered onto a Percoll gradient (d  1.088 gliter)
and centrifuged at 400  g for 30 min. The granulocyte pellet,
enriched mainly in neutrophils and EOs, was harvested and
depleted of erythrocytes by hypotonic saline lysis. At this point,
the granulocyte pellet was incubated for 30 min at 4°C with
anti-CD16 and anti-CD3 immunomagnetic beads, to remove
neutrophils and contaminating lymphocytes, respectively. EOs
were then eluted by passing the cells through the field of a
permanent magnet. Freshly purified EOs were resuspended at
3 106 cells per ml in PBS containing 1% BSA. Flow cytometry
analysis was performed on each EO preparation as follows: 50-l
aliquots of the single-cell preparations were incubated with
FITC-conjugated anti-CD16, peridinin–chlorophyll–protein
(perCP)-conjugated anti-CD3 and phycoerythrin (PE)-
conjugated anti-CD19 mAb (to identify neutrophils or contam-
inating lymphocytes), or as negative control, FITC-conjugated
isotype-matched Ab at a final concentration of 5 gml for 1 h
at 4°C in round-bottomed 96-well plates. After two washes in
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PBS, the cells were resuspended in PBS0.5% BSA before
analysis. Analysis was done by using FACSCalibur and
CELLQUEST software (Becton Dickinson). For the experiments,
we used only preparations that were composed of 97% EOs
(data not shown).
Real-Time Quantitative RT-PCR. Presence of S1PRs was screened
by PCR, and we assessed that only S1P1, S1P2, and S1P3 were
present (data not shown). Total mRNA from rat paws and
from human purified EOs was extracted by using TRIzol
reagent (GIBCO), according to the manufacturer’s recom-
mendations. Reverse transcription was performed, and 100 ng
of the RNA samples described above were used for quantita-
tive PCR. Samples were run in triplicate in 50-l reactions by
using an ABI PRISM 5700 sequence detector system (Applied
Biosystems). Samples were incubated at 50°C for 2 min and
95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C
for 1 min. SYBR-green oligonucleotides to detect both rat and
human S1P1, S1P2, and S1P3 receptors and rat RANTES,
CCR3, and eotaxin were specifically designed by using PRIMER
EXPRESS software (Applied Biosystems) and validated for their
specificity (Table 1). Relative quantification of target cDNA
was determined by arbitrarily setting the control value at 100,
and changes in cDNA content of a sample were expressed as
a multiple thereof. Differences in cDNA input were corrected
by normalizing signals obtained with primers specific for
GAPDH. TaqMan-based predeveloped assay reagents were
used for human Eotaxin, RANTES, and CCR3 by using a
commercially available kit (Applied Biosystems). mRNA copy
differences were corrected by using human GAPDH endoge-
nous control predeveloped assay reagent (Applied Biosys-
Table 1. Oligonucleotides used in SYBR green experiments
Oligonucleotide Sequence
Rat-S1P1-F 5-GGCCACCACCTACAAGCTCA-3
Rat-S1P1-R 5-CTTCCTTCCCGCAGAAACC-3
Rat-S1P2-F 5-CAGTGGCCAGGAACAGCAA-3
Rat-S1P2-R 5-TGCCGAGGAACAGGTACATG-3
Rat-S1P3-F 5-TGTCCGCTAGGAAGACGTTCA-3
Rat-S1P3-R 5-CCCTGAGGAACCACACTGTTG-3
Rat-GAPDH-F 5-ACCCATCACCATCTTCCAGGA-3
Rat-GAPDH-R 5-AGCCTTCTCCATGGTGGTGAA-3
Rat-CCR3-F 5-GGTCTTGCAGTATTGGCAGCA-3
Rat-CCR3-R 5-TGTCTTCTTCGCCCTCTGGAT-3
Rat-RANTES-F 5-GCCCACGTGAAGGAGTATTT-3
Rat-RANTES-R 5-TTGAACCCACTTCTTCTCTGG-3
Rat-scya11-F 5-GCTTGGCAAAGAGATCTGTGC-3
Rat-scya11-R 5-TTTGGTCCAGGTGCTTTGTG-3
Human-S1P1-F 5-GGGCCACCACCTACAAGCT-3
Human-S1P1-R 5-GCTGACAGGGCCACAAACAT-3
Human-S1P2-F 5-GCGCCATTGTGGTGGAAAA-3
Human-S1P2-R 5-CATTGCCGAGTGGAACTTGCT-3
Human-S1P3-F 5-GGTGATTGTGGTGAGCGTGTT-3
Human-S1P3-R 5-AGGCCACATCAATGAGGAAGA-3
F, forward; R, reverse.
Fig. 1. S1P local administration causes edema formation and EO infiltration.
(A) Subplantar administration of S1P (1, 3, and 10 g per paw) causes a
dose-dependent edema. Control animals received the vehicle used to dissolve
S1P. *, P 0.05; ***, P 0.001 vs. control. (B) The histology shows that a large
EO infiltrate (10) is present in rat paw 1 h after the injection of S1P (10 g).
(C) Higher magnification (40) of the area delimited by the square in B, where
eosinophilia is clearly visible. Data are expressed as mean  SEM.
Fig. 2. S1P increases S1PRs and CCR3 message in paw tissue. (A) S1P injection
(10 g) increases mRNA levels of S1P1, S1P2, and S1P3 receptors in the rat-paw
tissue. Receptor expression reaches its maximum at the 1-h time point (***, P
0.001 vs. its respective basal level). At the 5-h time point, when the edema
heals, whereas S1P2 and S1P3 expression returns to basal level, S1P1 expression
is significantly lower than its basal level (###, P 0.01). (B) CCR3 and RANTES
mRNA levels are undetectable in control tissue. After S1P injection (10 g)
CCR3 mRNA is strongly up-regulated (***, P  0.001), as opposed to RANTES
at the 1-h time point. CCR3 mRNA levels decrease significantly at the 5-h time
point, when the edema heals (***, P  0.001 vs. 1 h).
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tems). To exclude nonspecific amplification andor the for-
mation of primer dimers, control reactions were performed in
the absence of target cDNA. All of the experiments were run
in triplicate.
Human EO Chemotaxis. Chemotaxis assays were performed by
using 24-well transwell plates with an 8-m pore-size polycar-
bonate filter (Costar), as described (21). In brief, RPMI medium
1640 (GIBCO) containing either 8 ngml recombinant human
eotaxin (PeproTech, London) or 100 nM S1P (Tocris Cookson,
Bristol, U.K.) was placed in the lower chamber. We loaded 1 
105 highly purified EOs in the upper chamber. Cells were
incubated with a blocking anti-CCR3 Ab at 8 gml (R & D
Systems) for 30 min at 4°C or not incubated. All of the cells were
resuspended at 1  106 cells per ml. Transwells were then
incubated for 3 h at 37°C in a 5% CO2 humidified atmosphere.
Cell migration was determined by counting cells that had
migrated through the filter in five random high-power micro-
scope fields (40  800). All experiments were performed in
triplicate.
Rat Edema and Peritonitis. Male Wistar rats (Charles River Breed-
ing Laboratories, Lecco, Italy) weighing 200–250 g (n 6) were
lightly anaesthetized with enflurane 4%. Each rat received a
subplantar administration of S1P (1–10 g) or the vehicle
(0.04% BSA) in a final volume of 100 l. Paw volume was
measured by using a hydropletismometer (Ugo Basile, Varese,
Italy) immediately before subplantar injection and every 1 h for
6 h. The increase in paw volume was calculated by subtracting the
basal value. To induce peritonitis S1P (3 g per rat) or the
vehicle (0.04% BSA) were injected in the rat peritoneal (n  6)
cavity in a final volume of 500 l by using a 1-ml syringe. Rats
were killed after 1 h, and the peritoneal exudates were recovered
by washing the peritoneal cavity and a differential cell count
performed after staining with eosin by an observer who was
unaware of the treatment protocol.
Histology. Rat paws were fixed in neutral buffered formalin
before being embedded in paraffin. Sections (4 M) were
stained with hematoxylineosin and analyzed under light mi-
croscopy by an observer unaware of the treatment protocol.
Statistical Analysis. Data are expressed as mean SEM. The level
of statistical significance was determined by one-way ANOVA,
followed by Bonferroni’s t test for multiple comparisons by using
PRISM software (GraphPad, San Diego).
Results
S1P Causes Inflammation and EO Recruitment in Rat in Vivo. The
administration of S1P (1–10 g) in rat paw (n  6) causes a
dose-dependent edema that peaks at the 2-h time point (Fig.
1A). Histological analysis showed the presence of a large EO
infiltrate (Fig. 1 B and C). Examination of histological sections
histological obtained by six different animals showed that, at
the 2-h point, there were 27  0.5 EOs for high-power field
(HPF), whereas EOs were absent in the paw injected with the
vehicle. Next, to assess whether the observed phenomenon is
a feature only of the intraplantar injection, we i.p. adminis-
Fig. 3. S1P-induced EO migration. Dose-dependent migration of EOs after incubation with S1P (A); S1P-induced migration (108 M) is reduced significantly by
anti-CCR3 neutralizing Ab (8 gml) (B). Eotaxin has been used as a positive control. ***, P  0.001 vs. MEM; ##, P  0.01 vs. S1P. (C) Representative photos of
EO chemotaxis in vitro. Eotaxin (a; 8gml) or S1P (b; 40 ngml) causes EO chemotaxis, and incubation with anti-CCR3 antibodies reduces S1P-induced chemotaxis
significantly (c).
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tered S1P (3.10 g) into rats (n  6). The differentiated count
performed on the exudates harvested 1 h after the i.p.
administration showed that there was a consistent change in
the cell distribution. Indeed, the vehicle (BSA) caused an
increase in EOsHPF of 3.8  0.9%, whereas the doses of 3
and 10 g of S1P caused an increase in EOsHPF of 20  3%
and 30  5%, respectively (P  0.01 vs. vehicle).
RT-PCR Quantitative Studies: Chemokines and Endothelial Differenti-
ation Gene Receptors in Paw Tissue. Next, we addressed whether
there is up-regulation of S1PRs in the paw tissues injected with
S1P. RT-PCR quantitative analysis shows that, in basal con-
dition, S1P1 is the most abundantly expressed, as compared
with S1P2 and S1P3, whereas S1P4 and S1P5 are not detectable
(Fig. 2A). After administration of S1P, there is an increase in
the expression of S1P1 and S1P2 at a 2-h time point in rat-paw
tissue. At the 5-h time point, whereas S1P2 level returns to
basal value, S1P1 is significantly lower than its relative basal
(Fig. 2 A). CCR3 message is increased, as opposed to RANTES
(Fig. 2B), whereas eotaxin is undetectable in our experimental
conditions (data not shown). The increased expression of
CCR3 followed the edema profile and S1PRs expression,
peaking at the 2-h time point and declining 5 h thereafter when
the edema heals.
S1P Causes Chemotaxis of Human EOs. To further characterize the
effects of S1P on EO recruitment, we prepared a set of in vitro
experiments by using purified human EO. We find that S1P
causes a dose-dependent chemotaxis in vitro of human EOs with
a maximal increase in migration at 108 M (Fig. 3A). Because
CCR3 is a key player in EO chemotaxis, we tested the effect of
an anti-CCR3 Ab on S1P-induced EO chemotaxis, and we found
that an anti-CCR3 mAb (8 gml) significantly inhibited
(50%) S1P-induced EO migration (Fig. 3 B and C).
S1P Increases Message Expression of Its Receptors on Human EOs.
Highly purified human EO (97% purity, as assessed by f low
cytometry) expresses S1P1, S1P2, and S1P3, whereas S1P4 and
S1P5 are undetectable. Quantitative RT-PCR analysis shows
that human EO in basal condition display higher levels of S1P1
than S1P2 and S1P3 (Fig. 4). Incubation of EO with S1P 10 or
100 nM for 12 h increases the expression of S1P1, S1P2, and
S1P3 significantly (Fig. 4). Conversely, incubation for 18 h with
10 or 100 nM S1P reduces S1P1 expression vs. basal, whereas
S1P2 and S1P3 are not different from their relative basal
(Fig. 4).
S1P Causes Increased Expression of CCR3 and RANTES in EOs in Vitro.
S1P (10 and 100 nM) that is incubated for 12 h with human EO
causes an increase in CCR3 and RANTES message, whereas
eotaxin is undetectable in our experimental conditions (data not
shown). S1P (10 nM) causes an increase of 18,000-fold for CCR3
and 4,000-fold for RANTES (Fig. 5). A longer time of incubation
of S1P (10 and 100 nM) with EOs causes a loss of RNA message
and a significant reduction of RANTES below the basal level
(Fig. 5).
Discussion
Local administration into the rat paw of S1P causes an edema
characterized by a large EO infiltrate, which peaks at 2 h and it
is resolved after 5 h. A consistent and rapid EO infiltrate is
obtained also 1 h after i.p. administration of S1P. Thus, S1P
displays a potent and selective recruiting activity for EOs in two
different experimental models in vivo.
S1P explicates its activity through a receptorial mechanism
that involves a class of G protein-coupled receptors that were
recently renamed S1PRs. In control rat-paw tissues, we found
high levels of mRNA message for S1P1, whereas the message for
S1P2 receptor is 50 times less. S1P1, S1P2, and S1P3 mRNA
copies increased at the 2-h point (when the edema peaks) and
returned within basal levels at 5 h (when the edema resolves).
S1P2 mRNA levels were enhanced 60 times over the basal
value, indicating that this receptor is strongly up-regulated after
S1P stimulation. Indeed, S1P1 values were enhanced only about
three times because this receptor is highly expressed constitu-
tively and most likely can account mainly for physiological,
rather than pathological, signaling. Overall, this experimental
evidence implies that up-regulation of these two receptors is
crucial in the EO recruitment process that drives the observed
inflammatory response.
It is widely accepted that EO recruitment depends on a
complex cross-talk between several chemokines and cytokines,
and among these, RANTES and eotaxin are the critical stimuli
that modulate both EO trafficking and recruitment through
CCR3 (22). Basal levels of CCR3, eotaxin, and RANTES are
undetectable in our experimental conditions (i.e., in control
paw tissue). After S1P administration in rat paw, CCR3
receptor tissue level shifts from undetectable to 5,000
mRNA copies, as assessed by quantitative RT-PCR. Both
RANTES and eotaxin remained undetectable also in stimu-
lated conditions. This consistent increase in CCR3 message,
which is the receptor that mediates most of the EO functions
Fig. 4. S1P increases S1PRs expression on human EOs. Dose-dependent
increase in S1P1, S1P2, and S1P3 expression on human purified EOs after
incubation with MEM or S1P after 12 h. Incubation for 18 h causes a loss of
expression. *, P  0.05; **, P  0.01 vs. MEM; #, P  0.05 vs. S1P1 basal level.
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(23, 24), correlates well with the large EO infiltrate driven by
S1P paw injection.
S1P is stored in platelets, and these cells are the major source
of S1P in plasma (1). It has been shown that the platelet–
leukocyte interaction, as well as platelets alone, are involved in
allergic inflammation and airway remodeling (25, 26). The exact
mechanism by which platelet contributes to these processes in
not known. However, it is known that platelet-derived growth
factor receptor is tethered to S1P1 receptor, providing a platform
for integrative signaling by these two types of receptors, resulting
in activation and integration of downstream signal essentials for
cell locomotion (27, 28). Our results suggest that S1P could
represent the link among these cells that are involved in airway
inflammation.
It is worth noting that the concentration of S1P used in this
study is well within a pathophysiological range. Indeed, whereas
S1P levels in plasma and serum range 200–900 nM (17), the
amount injected in the paw to obtain edema coupled to EO
migration ranges 8–25 nM. Thus, it is feasible that this concen-
tration, being 30 times lower than the plasma levels, may be
reached at a site of an injury.
Human EOs in resting condition constitutively express S1P1
and, to a lower extent, S1P2 and S1P3 message, which is similar
to what happens in the rat-paw tissue. After stimulation in vitro
with S1P for 12 h, there is a dose-related increase in S1P1, S1P2,
and S1P3 receptor mRNA. Prolonged time of incubation leads
to a reduction in expression of S1P1 below basal levels, whereas
both S1P2 and S1P3 are not significantly different from their
basal level. These data are not surprising because it is known
that a prolonged exposition of cells to S1P leads to a reduction
in biological activity (29). Next, we evaluated whether S1P, if
it causes chemotaxis in vitro of purified human EOs already at
the dose of 1010 M, causes human EO chemotaxis in vitro in
a dose-dependent manner, suggesting an important role for
S1P in EO recruitment in human diseases. We then investi-
gated the role of CCR3, eotaxin, and RANTES. The most
striking result is that, in our experimental condition, we find
an increase of18,000 times in CCR3 message and 4,000 times
in RANTES message, whereas the eotaxin level is undetect-
able. These data indicate that S1P, by specific up-regulation of
CCR3 and RANTES in humans, drives EO recruitment. The
striking up-regulation of CCR3 message observed in vivo and
in vitro points toward a key role for S1P in regulating CCR3
expression in EOs. CCR3 is widely recognized as a key player
in allergic inf lammation, and it is known that lipids and
chemically related substances can up-regulate gene expression.
Thus, our data shed a light on a link between chemokine
signaling and S1P, already well characterized for Th2-like
responses in immune mediated events (30). However, it was
not clear from our results whether S1P-induced chemotaxis
through its receptors and in turn increased CCR3 message or
whether it could somehow also bind CCR3. We found that an
anti-CCR3 Ab, that selectively blocks the binding domain,
reverses of 50% S1P-induced chemotaxis implying that S1P
acts by means of the activation of its receptors and through
CCR3. This hypothesis is not unlikely because both S1PRs and
chemokine receptors are both G protein-coupled receptors. In
addition, CCR3 is a promiscuous binder for chemokines and
other factors that are not yet identified (22, 23, 30, 31) and S1P
could be one of these unidentified factors. In our experiments,
we did not detect eotaxin but we detected RANTES increase
that is known to play a pivotal role, both in vivo and in vitro,
in recruiting EOs at the site of inf lammation through CCR3
binding (23, 24).
Despite the enormous effort of the research, the recruitment
process of EOs in health and disease is still unclear. In particular,
the eosinophilia that accompanies allergic diseases is still matter
of debate (32). A recent study shows that S1P level increases in
the airways of asthmatic patients after segmental allergen chal-
lenge (11). S1P levels reach an average concentration of10 nM
in bronchial alveolar lavage (BAL) fluid of asthmatics, com-
pared with the baseline 1–2 nM concentration found in control
subjects. The S1P level (10 nM) is the same concentration used
in our in vitro study. Furthermore, in this study, CCR3 expression
correlates with the EO number present in human BAL after
segmental allergen challenge (33). Thus, these clinical results fit
well with our in vitro and in vivo data, confirming that S1P also
plays a role in the EO recruitment in vivo in humans. Recently,
it has been shown (34) that S1P is involved in mast cell
chemotaxis, further supporting a key role for this lipid in allergic
inflammation.
Fig. 5. S1P increases the message for CCR3 and RANTES on human EOs. Dose-dependent increase in mRNA copies of CCR3 and RANTES after incubation for
12 h with S1P. Longer time of incubation (18 h) causes a loss in expression. *, P  0.01; ***, P  0.001 vs. their relative basal values.
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In conclusion, we show that S1P acts as chemotactic agent for
human EOs in vitro and causes EO recruitment in vivo in two
different experimental models. This recruitment process de-
pends on (i) an increase in S1P1, S1P2, and S1P3 mRNA levels;
(ii) an increase in RANTES mRNA levels in human EOs only;
and (iii) an increase in CCR3 mRNA levels. Together, these data
may envisage a scenario in which, upon antigen stimulation, mast
cells (8, 9), dendritic cells (35), and platelet aggregates (36)
release S1P that recruits EOs, as well as determine an overall
cytokines production that drives the Th2 response. On this basis,
we suggest that an S1P antagonist, or interfering with S1P
synthesis, could represent a valuable therapeutic tool in diseases
such as allergies.
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